In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA 4-RET
暂无分享,去创建一个
Hiroshi Sato | S. Yano | K. Fukuda | S. Takeuchi | S. Arai | K. Kita | Azusa Tanimoto
[1] M. Ladanyi,et al. A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers , 2016, The Lancet. Oncology.
[2] D. Coppola,et al. Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma , 2016, Molecular Cancer Therapeutics.
[3] P. Stephens,et al. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations , 2016, Clinical Cancer Research.
[4] L. Borsu,et al. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF , 2015, Molecular Cancer Research.
[5] M. Zeiger,et al. The RET oncogene in papillary thyroid carcinoma , 2015, Cancer.
[6] A. Biryukov,et al. [Pooled Analysis of RET/PTC Gene Rearrangement Rate in Sporadic and Radiogenic Thyroid Papillary Carcinoma]. , 2015, Radiatsionnaia biologiia, radioecologiia.
[7] P. Stephens,et al. Identification and characterization of RET fusions in advanced colorectal cancer , 2015, Oncotarget.
[8] Meizhuo Zhang,et al. An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma , 2015, Genes, chromosomes & cancer.
[9] F. Tanaka,et al. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line , 2015, Cancer science.
[10] S. Iida,et al. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma , 2014, Cancer science.
[11] K. Kumamoto,et al. A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. , 2014, Carcinogenesis.
[12] H. Sakamoto,et al. Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer , 2014, Molecular Cancer Therapeutics.
[13] G. Sudhakar,et al. Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters , 2014, Tumor Biology.
[14] Koichi Goto,et al. RET fusion gene: Translation to personalized lung cancer therapy , 2013, Cancer science.
[15] Masao Iwata,et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. , 2013, Cancer letters.
[16] Yutaka Suzuki,et al. Identification of a lung adenocarcinoma cell line with CCDC6‐RET fusion gene and the effect of RET inhibitors in vitro and in vivo , 2013, Cancer science.
[17] H. Ji,et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Seungbok Lee,et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.
[19] Doron Lipson,et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.
[20] Yuki Togashi,et al. RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.
[21] Yasushi Totoki,et al. KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.
[22] Hiroshi Sakamoto,et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.
[23] A. Ryan,et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. , 2008, Cancer letters.
[24] K. Kito,et al. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES‐10 cells) highly expressing vascular endothelial growth factor and its receptor , 2006, Cancer science.
[25] M. Takahashi,et al. The GDNF/RET signaling pathway and human diseases. , 2001, Cytokine & growth factor reviews.
[26] Shunhua Xing,et al. Leucine Zipper-mediated Dimerization Is Essential for the PTC1 Oncogenic Activity* , 1997, The Journal of Biological Chemistry.
[27] N. Kohno,et al. Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions. , 1994, Oncology Report.
[28] H. Sato,et al. Establishment and biological characterization of an in vitro human cytomegalovirus latency model. , 1987, Virology.
[29] J. Ritz,et al. Activation of a novel human transforming gene, ret, by DNA rearrangement , 1985, Cell.
[30] T. Kohno,et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. , 2017, The Lancet. Respiratory medicine.
[31] K. Kiura,et al. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. , 2017, The journal of medical investigation : JMI.